Related Experiment Video
Updated: Mar 14, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Growth hormone delivery devices: current features and potential for enhanced treatment adherence
Tilman R Rohrer1, Reiko Horikawa2, Anne-Marie Kappelgaard3
1a Department of Pediatrics and Adolescent Medicine , Saarland University Medical Center , Homburg/Saar , Germany.
Introduction:
Adherence to daily growth hormone (GH) injections optimizes treatment benefit; however, adherence rates are sometimes poor. Reasons for poor adherence and persistence are multifaceted. GH injection devices are undergoing continual improvement to enhance adherence. Areas covered: This review evaluates published data on the evolution of GH injection devices to meet patients' needs and preferences, patients' perception of new devices and the projected impact of device developments on adherence. Published studies were identified through literature database searches including EMBASE and PubMed (January 1985-November 2015). Expert opinion: Patient needs and preferences trend towards convenient, easy-to-use devices that enable self-injection, minimize injection preparation steps by reducing the medication reconstitution and storage requirements, and reduce injection pain. In comparative studies, devices that patients considered easier to use than comparator devices were associated with reduced handling errors, fear of injection (needle anxiety/needle phobia) and pain upon needle insertion, and were thus preferred. A combination of the following items are expected to increase patient motivation to better adhere to therapy and improve treatment outcomes: advances in GH injection devices, educating patients regarding injection device and injection technique, and ongoing support from healthcare professionals, including comprehensive education about their condition, medication and expected outcomes.
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Stimuli-Activated

